These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 15380218)

  • 21. [A novel therapeutic drug: ramelteon].
    Miyamoto M
    Nihon Rinsho; 2009 Aug; 67(8):1595-600. PubMed ID: 19768947
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New melatonin (MT1/MT2) ligands: design and synthesis of (8,9-dihydro-7H-furo[3,2-f]chromen-1-yl) derivatives.
    Landagaray E; Ettaoussi M; Leclerc V; Traoré B; Perez V; Nosjean O; Boutin JA; Caignard DH; Delagrange P; Berthelot P; Yous S
    Bioorg Med Chem; 2014 Feb; 22(3):986-96. PubMed ID: 24417958
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, synthesis and melatoninergic potency of new N-acyl 8,9-dihydro-4-methoxy-7H-2-benzo[de]quinolinalkanamines.
    Tsotinis A; Eleutheriades A; Hough KA; Davidson K; Sugden D
    Bioorg Chem; 2007 Apr; 35(2):189-204. PubMed ID: 17223160
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of
    Ferreira MA; Azevedo H; Mascarello A; Segretti ND; Russo E; Russo V; Guimarães CRW
    J Med Chem; 2021 Feb; 64(4):1904-1929. PubMed ID: 33626870
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis of a novel series of tricyclic dihydrofuran derivatives: discovery of 8,9-dihydrofuro[3,2-c]pyrazolo[1,5-a]pyridines as melatonin receptor (MT1/MT2) ligands.
    Koike T; Takai T; Hoashi Y; Nakayama M; Kosugi Y; Nakashima M; Yoshikubo S; Hirai K; Uchikawa O
    J Med Chem; 2011 Jun; 54(12):4207-18. PubMed ID: 21568291
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis and biological evaluation of new naphtho- and quinolinocyclopentane derivatives as potent melatoninergic (MT
    Duroux R; Rami M; Landagaray E; Ettaoussi M; Caignard DH; Delagrange P; Melnyk P; Yous S
    Eur J Med Chem; 2017 Dec; 141():552-566. PubMed ID: 29102176
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of 2-(4-benzyloxyphenyl)-N- [1-(2-pyrrolidin-1-yl-ethyl)-1H-indazol-6-yl]acetamide, an orally efficacious melanin-concentrating hormone receptor 1 antagonist for the treatment of obesity.
    Souers AJ; Gao J; Brune M; Bush E; Wodka D; Vasudevan A; Judd AS; Mulhern M; Brodjian S; Dayton B; Shapiro R; Hernandez LE; Marsh KC; Sham HL; Collins CA; Kym PR
    J Med Chem; 2005 Mar; 48(5):1318-21. PubMed ID: 15743174
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recent advances in melatonin receptor ligands.
    Zlotos DP
    Arch Pharm (Weinheim); 2005 Jun; 338(5-6):229-47. PubMed ID: 15952241
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular cloning and pharmacological characterization of rat melatonin MT1 and MT2 receptors.
    Audinot V; Bonnaud A; Grandcolas L; Rodriguez M; Nagel N; Galizzi JP; Balik A; Messager S; Hazlerigg DG; Barrett P; Delagrange P; Boutin JA
    Biochem Pharmacol; 2008 May; 75(10):2007-19. PubMed ID: 18384758
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design and synthesis of 1-(2-alkanamidoethyl)-6-methoxy-7-azaindole derivatives as potent melatonin agonists.
    Jeanty M; Suzenet F; Delagrange P; Nosjean O; Boutin JA; Caignard DH; Guillaumet G
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2316-9. PubMed ID: 21420861
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chronobiotic activity of N-[2-(2,7-dimethoxyfluoren-9-yl)ethyl]-propanamide. Synthesis and melatonergic pharmacology of fluoren-9-ylethyl amides.
    Epperson JR; Bruce MA; Catt JD; Deskus JA; Hodges DB; Karageorge GN; Keavy DJ; Mahle CD; Mattson RJ; Ortiz AA; Parker MF; Takaki KS; Watson BT; Joseph P Yevich
    Bioorg Med Chem; 2004 Sep; 12(17):4601-11. PubMed ID: 15358287
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recent advances in the development of melatonin MT(1) and MT(2) receptor agonists.
    Mor M; Rivara S; Pala D; Bedini A; Spadoni G; Tarzia G
    Expert Opin Ther Pat; 2010 Aug; 20(8):1059-77. PubMed ID: 20533893
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Case of Unilateral Hypnic Headache: Rapid Response to Ramelteon, a Selective Melatonin MT1/MT2 Receptor Agonist.
    Arai M
    Headache; 2015; 55(7):1010-1. PubMed ID: 26121162
    [No Abstract]   [Full Text] [Related]  

  • 34. Tasimelteon: first global approval.
    Dhillon S; Clarke M
    Drugs; 2014 Mar; 74(4):505-11. PubMed ID: 24610704
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Specific melatonin receptor promotes a deeper sleep.
    Harrington M
    Lab Anim (NY); 2012 Jan; 41(2):31. PubMed ID: 22261877
    [No Abstract]   [Full Text] [Related]  

  • 36. Melatonin reverses the expression of morphine-induced conditioned place preference through its receptors within central nervous system in mice.
    Han J; Xu Y; Yu CX; Shen J; Wei YM
    Eur J Pharmacol; 2008 Oct; 594(1-3):125-31. PubMed ID: 18706407
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fresh from the pipeline: Ramelteon.
    Buysse D; Bate G; Kirkpatrick P
    Nat Rev Drug Discov; 2005 Nov; 4(11):881-2. PubMed ID: 16299918
    [No Abstract]   [Full Text] [Related]  

  • 38. Stimulatory effects of a melatonin receptor agonist, ramelteon, on BDNF in mouse cerebellar granule cells.
    Imbesi M; Uz T; Dzitoyeva S; Manev H
    Neurosci Lett; 2008 Jul; 439(1):34-6. PubMed ID: 18501512
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration.
    Dziadulewicz EK; Bevan SJ; Brain CT; Coote PR; Culshaw AJ; Davis AJ; Edwards LJ; Fisher AJ; Fox AJ; Gentry C; Groarke A; Hart TW; Huber W; James IF; Kesingland A; La Vecchia L; Loong Y; Lyothier I; McNair K; O'Farrell C; Peacock M; Portmann R; Schopfer U; Yaqoob M; Zadrobilek J
    J Med Chem; 2007 Aug; 50(16):3851-6. PubMed ID: 17630726
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 2-[4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy]-N-(methylsulfonyl)acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug.
    Kuwano K; Hashino A; Asaki T; Hamamoto T; Yamada T; Okubo K; Kuwabara K
    J Pharmacol Exp Ther; 2007 Sep; 322(3):1181-8. PubMed ID: 17545310
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.